Personalized medicine incorporates genetic information into medical practice so as to optimize the management of chronic diseases. In
rare diseases, such as
heart cancer (incidence 0.0017-0.33%), this may be elusive. Ninety-five percent of the cases are due to secondary involvementwith the
neoplasm originating in the lungs, breasts, kidney, blood, or skin. The clinical manifestations of
heart tumors (benign or malignant) include
heart failure,
hypertension, and
cardiac arrhythmias of varying severity, frequently resulting in blood vessel emboli, including
strokes. This study aims to explain the pathophysiology and contribute to a P4 medicine model for use by cardiologists, pathologists, and oncologists. We created six gene/
protein heart-related and
tumor-related targets high-confidence interactomes, which unfold the main pathways that may lead to
cardiac diseases (
heart failure,
hypertension,
coronary artery disease, arrhythmias), i.e., the sympathetic nervous system, the
renin-
angiotensin-
aldosterone axis and the
endothelin pathway, and excludes others, such as the K
oxidase or
cytochrome P450 pathways. We concluded that
heart cancer patients could be affected by
beta-adrenergic blockers,
ACE inhibitors, QT-prolonging
antiarrhythmic drugs,
antibiotics, and
antipsychotics. Interactomes may elucidate unknown pathways, adding to patient/survivor wellness during/after chemo- and/or radio-
therapy.